tirzepatide: What to Expect Before and After Tirzepatide certified physicians Tirzepatide Weight Loss Options |

[4] In the SURMOUNT-1 obesity trial, a 72-week placebo-controlled study in 2,539 adults with obesity (without diabetes), mean weight change was 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses versus 3.1% for placebo

4% (placebo) Waist Circumference: Reduced by 9.2 cm (4.5 mg) vs

Journal of Toxicology and Environmental Health, Part B 17:341368

Bariatric surgery may be considered for individuals who have struggled to achieve significant weight loss through traditional methods and require additional support

Additionally, those with type 2 diabetes or individuals at a heightened risk of cardiovascular disease are also suitable candidates for this treatment

A: If a code doesnt apply, double-check its terms